Scopus h-index:84
Article:200
Review Article:54
Comment/Debate:20
Letter:4
Editorial:2
Chapter:9
Recent Artifacts
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021
- Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfb-Dependent Mechanisms
- Strategies to overcome DC dysregulation in the tumor microenvironment
- NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
- TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer
- Dark genome, bright ideas: Recent approaches to harness transposable elements in immunotherapies
- Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (Nature Medicine, (2022), 28, 4, (626-629), 10.1038/s41591-022-01681-x)
- Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1
- Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
- Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer